However, it is important to acknowledge that the optimal second-line treatment for patients with HER2-positive tumours who progress following first-line therapy with a chemotherapy doublet plus trastuzumab, with or without pembrolizumab, remains uncertain. This evidence concerns the gene ERBB2 and neoplasm.